

## Overview of Ongoing and Completed Opioid Related OIG Studies—As of September 30, 2020

### I. Prescribing Focused Work

#### a. Medicare

- i. Medicare Part D Payments for Transmucosal Immediate-Release Fentanyl Drugs ([W-00-20-35846](#)) *Ongoing Audit*
- ii. Data Brief: Opioid Use in Medicare Part D in 2020 ([OEI-02-20-00400](#)) *Ongoing Evaluation*
- iii. Utilization of Medication-Assisted Treatment in Medicare ([OEI-02-20-00390](#)) *Ongoing Evaluation*
- iv. Data Brief: Medicare Part D Beneficiaries at Serious Risk of Opioid Misuse or Overdose: A Closer Look. May 2020 ([OEI-02-19-00130](#))
- v. Toolkit for Calculating Opioid Levels and Identifying Patients At Risk of Misuse or Overdose: R and SQL Programming Code. May 2020 ([OEI-02-17-00561](#))
- vi. Data Brief: Opioid Use in Medicare Part D Continued to Decline in 2019, but Vigilance Is Needed as COVID-19 Raises New Concerns. August 2020 ([OEI-02-20-00320](#))
- vii. Data Brief: Opioid Use in Medicare Part D in Missouri. September 2019 ([OEI-02-19-00391](#))
- viii. Data Brief: Opioid Use Decreased in Medicare Part D, While Medication-Assisted Treatment Increased. July 2019 ([OEI-02-19-00390](#))
- ix. Data Brief: Concerns About Opioid Use in Medicare Part D in the Appalachian Region. April 2019 ([OEI-02-18-00224](#))
- x. Data Brief: Opioid Use in Medicare Part D Remains Concerning. June 2018 ([OEI-02-18-00220](#))
- xi. Toolkit: Using Data Analysis To Calculate Opioid Levels and Identify Patients At Risk of Misuse or Overdose. June 2018 ([OEI-02-17-00560](#))
- xii. Data Brief: Opioid Use in Medicare Part D: Concerns about Extreme Use and Questionable Prescribing. July 2017 ([OEI-02-17-00250](#))
- xiii. Data Brief: High Part D Spending on Opioids and Substantial Growth in Compounded Drugs Raise Concerns. June 2016 ([OEI-02-16-00290](#))
- xiv. Data Brief: Questionable Billing and Geographic Hotspots Point to Potential Fraud and Abuse in Medicare Part D. June 2015 ([OEI-02-15-00190](#))
- xv. Retail Pharmacies With Questionable Part D Billing. May 2012 ([OEI-02-09-00600](#))

#### b. Medicaid

- i. Opioids in Medicaid: Review of Extreme Use and Overprescribing in the Appalachian Region. ([OEI-05-19-00410](#)) *Ongoing Evaluation*
- ii. National Review of Opioid Prescribing in Medicaid Is Not Yet Possible. August 2019 ([OEI-05-18-00480](#))
- iii. Data Brief: Opioids in Ohio Medicaid: Review of Extreme Use and Prescribing. July 2018 ([OEI-05-18-00010](#))

#### c. Other HHS Programs

- i. FDA's Risk Evaluation and Mitigation Strategies: Uncertain Effectiveness in Addressing the Opioid Crisis. September 2020 ([OEI-01-17-00510](#))
- ii. Review of Opioid Use in Indian Health Service ([OEI-05-18-00470](#)) *Ongoing Evaluation*
- iii. Prescription Opioid Drug Abuse and Misuse Prevention—Prescription Drug Monitoring Programs ([W-00-18-59428](#)) *Partially Completed Audit Series*
  1. Washington State Made Progress Toward Achieving Program Goals for Enhancing Its Prescription Drug Monitoring Program. April 2019 ([A-09-18-01001](#))
  2. The University of Kentucky Made Progress Toward Achieving Program Goals for Enhancing Its Prescription Drug Monitoring Program. May 2019 ([A-04-18-02012](#))

3. New York Achieved Program Goals for Enhancing Its Prescription Drug Monitoring Program. August 2019 ([A-02-18-02001](#))
4. California Made Progress Toward Achieving Program Goals for Enhancing Its Prescription Drug Monitoring Program. December 2019 ([A-09-18-01006](#))
- iv. IHS Needs to Improve Oversight of Its Hospitals' Opioid Prescribing and Dispensing Practices and Consider Centralizing Its Information Technology Functions. July 2019 ([A-18-17-11400](#))
- v. States' Use of the Child Welfare Information Systems To Monitor Medication Prescribed to Children in Foster Care ([W-00-18-59434](#)) *Ongoing Audit*
  1. Ohio Did Not Ensure the Accuracy and Completeness of Psychotropic and Opioid Medication Information Recorded in Its Child Welfare Information System for Children in Foster Care. July 2020 ([A-05-18-00007](#))
- vi. HHS Information System Security Controls to Track Prescription Drug Disbursements. November 2017 ([A-18-16-30540](#))

## **II. Treatment Focused Work**

### **a. Medicaid**

- i. CMS Should Pursue Strategies To Increase the Number of At Risk Beneficiaries Acquiring Naloxone Through Medicaid. September 2020 ([OEI-BL-18-00360](#))
- ii. Review of Medicaid Claims for Opioid Treatment Program Services ([W-00-17-31523](#)) *Partially Completed Audit Series*
  1. New York Claimed Tens of Millions of Dollars for Opioid Treatment Program Services That Did Not Comply With Medicaid Requirements Intended To Ensure the Quality of Care Provided to Beneficiaries. February 2020 ([A-02-17-01021](#))
- iii. Provider Shortages and Limited Availability of Behavioral Health Services in New Mexico's Medicaid Managed Care. September 2019 ([OEI-02-17-00490](#))

### **b. Other HHS Programs**

- i. Data Snapshot: MAT from Providers Waivered at the Highest Patient-Limit Level ([OEI-BL-20-00260](#)), *Ongoing Evaluation*
- ii. Report in Brief: Geographic Disparities Affect Access to Buprenorphine Services for Opioid Use Disorder. January 2020 ([OEI-12-17-00240](#))
- iii. Report in Brief: States' Use of Grant Funding for a Targeted Response to the Opioid Crisis. March 2020 ([OEI-BL-18-00460](#))
- iv. Access to Medication-Assisted Treatment at Health Centers ([OEI-BL-19-00320](#)) *Ongoing Evaluation (On Hold)*
- v. Opioid Treatment Program Experiences During the COVID-19 Pandemic ([W-00-20-59447](#)) *Ongoing Audit*
- vi. SAMHSA's Oversight of Accreditation Bodies for Opioid Treatment Programs ([W-00-18-59035](#)) *Partially Completed Audit Series*
  1. SAMHSA's Oversight of Accreditation Bodies for Opioid Treatment Programs Did Not Comply With Some Federal Requirements. March 2020 ([A-09-18-01007](#))
- vii. HRSA's Monitoring Did Not Always Ensure Health Centers' Compliance with Federal Requirements for HRSA's Access Increases in Mental Health and Substance Abuse Services Supplemental Grant Funding. July 2020 ([A-02-18-02010](#))
- viii. Projects for Assistance in Transition from Homelessness Program ([W-00-19-50100](#)) *Ongoing Audit*
- ix. Access Increases in Mental Health and Substance Abuse Services Funding for Health Centers ([W-00-19-59442](#)) *Ongoing Audit*

- x. Post-Award State or Tribal Audits of Substance Abuse and Mental Health Services Administration's Opioid Response Grants. ([W-00-20-59441](#)) *Ongoing Audit Series*
- xi. SAMHSA Followed Grant Regulations and Program-Specific Requirements When Awarding State Targeted Response to the Opioid Crisis Grants. March 2019 ([A-03-17-03302](#))
- xii. New York Did Not Provide Adequate Stewardship of Substance Abuse Prevention and Treatment Block Grant Funds. March 2019 ([A-02-17-02009](#))

### **III. Work Focused on Both Treatment and Prescribing**

#### **a. Review of States' Oversight of Opioid Prescribing and Monitoring of Opioid Use ([W-00-18-59440](#))**

##### *Partially Completed Audit Series*

- i. Factsheet Rollup Report: Oversight of Opioid Prescribing and Monitoring of Opioid Use: States Have Taken Action To Address the Opioid Epidemic. July 2019 ([A-09-18-01005](#))
- ii. Factsheet: Kentucky's Oversight of Opioid Prescribing and Monitoring of Opioid Use. March 2020 ([A-04-19-02022](#))
- iii. Factsheet: Alabama's Oversight of Opioid Prescribing and Monitoring of Opioid Use. November 2019 ([A-04-19-00125](#))
- iv. Factsheet: Ohio's Oversight of Opioid Prescribing and Monitoring of Opioid Use. July 2020 ([A-05-19-00036](#))
- v. Factsheet: Texas Oversight of Opioid Prescribing and Monitoring of Opioid Use. March 2019 ([A-06-18-04000](#))
- vi. Factsheet: West Virginia's Oversight of Opioid Prescribing and Monitoring of Opioid Use. March 2019 ([A-03-18-03302](#))
- vii. Factsheet: Tennessee's Oversight of Opioid Prescribing and Monitoring of Opioid Use. February 2019 ([A-04-18-00124](#))
- viii. Factsheet: Nevada's Oversight of Opioid Prescribing and Monitoring of Opioid Use. February 2019 ([A-09-18-01004](#))
- ix. Factsheet: New Hampshire's Oversight of Opioid Prescribing and Monitoring of Opioid Use. February 2019 ([A-01-18-01501](#))
- x. Factsheet: Utah's Oversight of Opioid Prescribing and Monitoring of Opioid Use. February 2019 ([A-07-18-05115](#))
- xi. Factsheet: Nebraska's Oversight of Opioid Prescribing and Monitoring of Opioid Use. January 2019 ([A-07-18-06080](#))
- xii. Factsheet: Washington's Oversight of Opioid Prescribing and Monitoring of Opioid Use. December 2018 ([A-09-18-02001](#))

#### **b. Services for American Indians and Alaska Natives Administered by a Federally Qualified Health Center ([W-00-17-59052](#))**

- i. The Penobscot Indian Nation Did Not Meet All Federal and Tribal Health and Safety Requirements. November 2018 ([A-01-17-01502](#))
- ii. The Passamaquoddy Tribe's Pleasant Point Health Center Did Not Always Meet Federal and Tribal Health and Safety Requirements. July 2018 ([A-01-17-01500](#))
- iii. The Passamaquoddy Tribe's Pleasant Point Health Center Needs to Improve Its Medical-Referral Process. March 2019 ([A-01-17-01503](#))

For more detail on OIG's opioid work, visit:

<https://oig.hhs.gov/reports-and-publications/featured-topics/opioids/>